SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

CHRS

Coherus Oncology, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the March 9 earnings release and call for actual financial performance, LOQTORZI sales trends, and updates on clinical development. The current lack of data limits immediate trading implications.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.65
T+0 close · Mar 2, 2026 · via day close
Latest settled
−0.61%
T+60 · $1.64
Vs SPY
−9.93%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $1.65entry
  2. T+1 · 9mo ago 0.00%α +0.91% · $1.65
  3. T+5 · 8mo ago +16.97%α +18.18% · $1.93
  4. T+20 · 8mo ago −3.03%α +4.91% · $1.60
  5. T+60 · 6mo ago −0.61%α −9.93% · $1.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus Oncology announced it will release its full-year and fourth-quarter 2025 financial results on March 9, 2026, followed by a conference call. The press release contains no actual financial data, only logistical details for the upcoming earnings announcement.

Key Facts

  • Coherus Oncology will release 2025 full-year and Q4 financial results on March 9, 2026, after market close.
  • Management will host a conference call at 4:30 p.m. ET on March 9 to discuss results and provide a business update.
  • No financial figures or operational updates were disclosed in this announcement.
  • The company uses its investor relations website for material disclosures under Regulation FD.

Financial Impact

No financial data disclosed in this release

Risk Factors

  • Earnings could miss expectations given the company's small market cap ($250M) and reliance on a single commercial product.
  • No forward-looking guidance is provided in this release, increasing uncertainty ahead of the report.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247524

Track record

15 reports on CHRS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026